Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.
Saved in:
| Title: | Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. |
|---|---|
| Authors: | Naicker V; South African Medical Research Council, Durban, South Africa., Laher F; Faculty of Health Sciences, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Seaton KE; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Allen M; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Yates NL; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Mkhize NN; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Saunders K; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Heptinstall J; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Malahleha M; Synergy Biomed Research Institute, East London, South Africa., Mngadi K; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Daniels B; South African Medical Research Council, Durban, South Africa., Innes C; Aurum Institute, Klerksdorp Research Centre, Klerksdorp, South Africa., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Modise T; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Bekker V; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Furch B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Phogat S; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.; GSK, Wavre, Belgium., Diazgranados CA; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America., Gurunathan S; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America., Koutsoukos M; GSK, Wavre, Belgium., Van Der Meeren O; Previously GSK, Rixensart, Belgium., Roxby AC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; University of Washington Departments of Medicine and Global Health, Seattle, Washington, United States of America., Ferrari G; Department of Surgery, Center for Human System Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America., Morris L; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Montefiori D; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Tomaras GD; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. |
| Source: | PLOS global public health [PLOS Glob Public Health] 2024 Sep 20; Vol. 4 (9), pp. e0003319. Date of Electronic Publication: 2024 Sep 20 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 9918283779606676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-3375 (Electronic) Linking ISSN: 27673375 NLM ISO Abbreviation: PLOS Glob Public Health Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39302924 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Naicker+V%22">Naicker V</searchLink>; South African Medical Research Council, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Laher+F%22">Laher F</searchLink>; Faculty of Health Sciences, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Bekker+LG%22">Bekker LG</searchLink>; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.<br /><searchLink fieldCode="AU" term="%22Seaton+KE%22">Seaton KE</searchLink>; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Allen+M%22">Allen M</searchLink>; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22De+Rosa+S%22">De Rosa S</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Yates+NL%22">Yates NL</searchLink>; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Mkhize+NN%22">Mkhize NN</searchLink>; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Saunders+K%22">Saunders K</searchLink>; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Heptinstall+J%22">Heptinstall J</searchLink>; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Malahleha+M%22">Malahleha M</searchLink>; Synergy Biomed Research Institute, East London, South Africa.<br /><searchLink fieldCode="AU" term="%22Mngadi+K%22">Mngadi K</searchLink>; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Daniels+B%22">Daniels B</searchLink>; South African Medical Research Council, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Innes+C%22">Innes C</searchLink>; Aurum Institute, Klerksdorp Research Centre, Klerksdorp, South Africa.<br /><searchLink fieldCode="AU" term="%22Yu+C%22">Yu C</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Modise+T%22">Modise T</searchLink>; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Bekker+V%22">Bekker V</searchLink>; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Grunenberg+N%22">Grunenberg N</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Furch+B%22">Furch B</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Miner+MD%22">Miner MD</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Phogat+S%22">Phogat S</searchLink>; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Diazgranados+CA%22">Diazgranados CA</searchLink>; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Gurunathan+S%22">Gurunathan S</searchLink>; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Koutsoukos+M%22">Koutsoukos M</searchLink>; GSK, Wavre, Belgium.<br /><searchLink fieldCode="AU" term="%22Van+Der+Meeren+O%22">Van Der Meeren O</searchLink>; Previously GSK, Rixensart, Belgium.<br /><searchLink fieldCode="AU" term="%22Roxby+AC%22">Roxby AC</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; University of Washington Departments of Medicine and Global Health, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Ferrari+G%22">Ferrari G</searchLink>; Department of Surgery, Center for Human System Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Morris+L%22">Morris L</searchLink>; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Montefiori+D%22">Montefiori D</searchLink>; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22McElrath+MJ%22">McElrath MJ</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.<br /><searchLink fieldCode="AU" term="%22Tomaras+GD%22">Tomaras GD</searchLink>; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Moodie+Z%22">Moodie Z</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229918283779606676%22">PLOS global public health</searchLink> [PLOS Glob Public Health] 2024 Sep 20; Vol. 4 (9), pp. e0003319. <i>Date of Electronic Publication: </i>2024 Sep 20 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918283779606676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2767-3375 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227673375%22">27673375 </searchLink><i>NLM ISO Abbreviation: </i>PLOS Glob Public Health <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39302924 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1371/journal.pgph.0003319 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e0003319 Titles: – TitleFull: Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Naicker V – PersonEntity: Name: NameFull: Laher F – PersonEntity: Name: NameFull: Bekker LG – PersonEntity: Name: NameFull: Seaton KE – PersonEntity: Name: NameFull: Allen M – PersonEntity: Name: NameFull: De Rosa S – PersonEntity: Name: NameFull: Yates NL – PersonEntity: Name: NameFull: Mkhize NN – PersonEntity: Name: NameFull: Saunders K – PersonEntity: Name: NameFull: Heptinstall J – PersonEntity: Name: NameFull: Malahleha M – PersonEntity: Name: NameFull: Mngadi K – PersonEntity: Name: NameFull: Daniels B – PersonEntity: Name: NameFull: Innes C – PersonEntity: Name: NameFull: Yu C – PersonEntity: Name: NameFull: Modise T – PersonEntity: Name: NameFull: Bekker V – PersonEntity: Name: NameFull: Grunenberg N – PersonEntity: Name: NameFull: Furch B – PersonEntity: Name: NameFull: Miner MD – PersonEntity: Name: NameFull: Phogat S – PersonEntity: Name: NameFull: Diazgranados CA – PersonEntity: Name: NameFull: Gurunathan S – PersonEntity: Name: NameFull: Koutsoukos M – PersonEntity: Name: NameFull: Van Der Meeren O – PersonEntity: Name: NameFull: Roxby AC – PersonEntity: Name: NameFull: Ferrari G – PersonEntity: Name: NameFull: Morris L – PersonEntity: Name: NameFull: Montefiori D – PersonEntity: Name: NameFull: McElrath MJ – PersonEntity: Name: NameFull: Tomaras GD – PersonEntity: Name: NameFull: Moodie Z IsPartOfRelationships: – BibEntity: Dates: – D: 20 M: 09 Text: 2024 Sep 20 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2767-3375 Numbering: – Type: volume Value: 4 – Type: issue Value: 9 Titles: – TitleFull: PLOS global public health Type: main |
| ResultId | 1 |
